Zydus Lifesciences Partners with CVS Caremark to Add Key Diabetes Products

Zydus Lifesciences Ltd has announced a strategic agreement with CVS Caremark to include its products, Zituvio, Zituvimet, and Zituvimet XR, in CVS's formulary starting January 1, 2025. This partnership aims to enhance access to these diabetes medications, which are designed to improve metabolic disorder management. The inclusion of Zydus products reflects a growing recognition of their therapeutic value in treating diabetes. This collaboration is expected to significantly benefit patients and strengthen Zydus's presence in the U.S. pharmaceutical market.

Source: Business Standard.Zydus Lifesciences Ltd has announced a strategic agreement with CVS Caremark to include its products, Zituvio, Zituvimet, and Zituvimet XR, in CVS's formulary starting January 1, 2025. This partnership aims to enhance access to these diabetes medications, which are designed to improve metabolic disorder management. The inclusion of Zydus products reflects a growing recognition of their therapeutic value in treating diabetes. This collaboration is expected to significantly benefit patients and strengthen Zydus's presence in the U.S. pharmaceutical market.

 

Zydus Lifesciences Ltd has announced a strategic agreement with CVS Caremark to include its products, Zituvio, Zituvimet, and Zituvimet XR, in CVS's formulary starting January 1, 2025. This partnership aims to enhance access to these diabetes medications, which are designed to improve metabolic disorder management. The inclusion of Zydus products reflects a growing recognition of their therapeutic value in treating diabetes. This collaboration is expected to significantly benefit patients and strengthen Zydus's presence in the U.S. pharmaceutical market.

Source: Business Standard.